Skip to main content
Livermore
Livermore
ZHEN

D. E. Shaw & Co., Inc.

SEC CIK
0001009207
Latest filing
Aug 14, 2026

ALNY holding history

Alnylam Pharmaceuticals, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ALNY overviewAll 13F holders of ALNYFull Q2 2026 holdings

Shares (Q2 2026)
1,104,109
Value
$332.4M
% of portfolio
0.2%
Quarters held
22
Since Q1 2021
Holdings of ALNY by D. E. Shaw & Co., Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,104,109$332.4M0.2%+45,047+4.3%AddedHolders
Q1 20261,059,062$350.4M0.3%+614,569+138.3%AddedHolders
Q4 2025444,493$176.8M0.1%+245,076+122.9%AddedHolders
Q3 2025199,417$90.9M0.1%+91,141+84.2%AddedHolders
Q2 2025108,276$35.3M<0.1%−181,586−62.6%ReducedHolders
Q1 2025289,862$78.3M0.1%−73,223−20.2%ReducedHolders
Q4 2024363,085$85.4M0.1%+30,780+9.3%AddedHolders
Q3 2024332,305$91.4M0.1%+52,907+18.9%AddedHolders
Q2 2024279,398$67.9M0.1%+176,011+170.2%AddedHolders
Q1 2024103,387$15.5M<0.1%+7,843+8.2%AddedHolders
Q4 202395,544$18.3M<0.1%−108,548−53.2%ReducedHolders
Q3 2023204,092$36.1M0.1%−44,180−17.8%ReducedHolders
Q2 2023248,272$47.2M0.1%+16,927+7.3%AddedHolders
Q1 2023231,345$46.3M0.1%+54,929+31.1%AddedHolders
Q4 2022176,416$41.9M0.1%+25,272+16.7%AddedHolders
Q3 2022151,144$30.3M0.1%+15,221+11.2%AddedHolders
Q2 2022135,923$19.8M<0.1%+121,040+813.3%AddedHolders
Q1 202214,883$2.43M<0.1%−31,457−67.9%ReducedHolders
Q4 202146,340$7.86M<0.1%+13,277+40.2%AddedHolders
Q3 202133,063$6.24M<0.1%−3,345−9.2%ReducedHolders
Q2 202136,408$6.17M<0.1%−41,495−53.3%ReducedHolders
Q1 202177,903$11.0M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.